FDA label 6e590c89-25f1-4bb8-bf63-111fd2a2561f
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- 0a4ad0db-ce67-4724-91d2-88258c2cc9f8
- SPL ID
- 6e590c89-25f1-4bb8-bf63-111fd2a2561f
- Version
- 5
- Effective date
- 2023-12-07
- Source export date
- 2026-11-13
- Source partition
- 9
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0009-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/48e89e7994339d0e23bed7c09f727a47746d1fbd440ad66960650182851cb8a9/drug-label-0009-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:08:15
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 6e590c89-25f1-4bb8-bf63-111fd2a2561f | id | |
| spl set id | 0a4ad0db-ce67-4724-91d2-88258c2cc9f8 | set_id |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS Hepatic injury: Use of EXSERVAN is not recommended in patients with baseline elevations of serum aminotransferases greater than 5 times upper limit of normal; discontinue EXSERVAN if there is evidence of liver dysfunction ( 5.1 ) Neutropenia: Advise patients to report any febrile illness ( 5.2 ) Interstitial lung disease: Discontinue EXSERVAN if interstitial lung disease develops ( 5.3 ) 5.1 Hepatic Injury EXSERVAN can cause liver injury. Cases of drug-induced liver injury, some of which were fatal, have been reported in patients taking riluzole. Asymptomatic elevations of hepatic transaminases have also been reported, and in some patients have recurred upon rechallenge with riluzole. In clinical studies, the incidence of elevations in hepatic transaminases was greater in riluzole-treated patients than in placebo-treated patients. The incidence of elevations of ALT above 5 times the upper limit of normal (ULN) was 2% in riluzole-treated patients. Maximum increases in ALT occurred within 3 months after starting riluzole. About 50% and 8% of riluzole-treated patients in pooled controlled efficacy studies (Studies 1 and 2) had at least one elevated ALT level above ULN and above 3 times ULN, respectively [see Clinical Studies ( 14 )]. Monitor patients for signs and symptoms of hepatic injury, every month for the first 3 months of treatment, and periodically thereafter. The use of EXSERVAN is not recommended if patients develop hepatic transaminases levels greater than 5 times the ULN. Discontinue EXSERVAN if there is evidence of liver dysfunction (e.g., elevated bilirubin). Concomitant use with other hepatotoxic drugs may increase the risk for hepatotoxicity [see Drug Interactions ( 7.3 )]. 5.2 Neutropenia EXSERVAN can cause neutropenia. Cases of severe neutropenia (absolute neutrophil count less than 500 per mm 3 ) within the first 2 months of riluzole treatment have been reported. Advise patients to report febrile illnesses. 5.3 Interstitial Lung Disease EXSERVAN can cause interstitial lung disease, including hypersensitivity pneumonitis. Discontinue EXSERVAN immediately if interstitial lung disease develops.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described below and elsewhere in the labeling: Hepatic Injury [see Warnings and Precautions ( 5.1 )] Neutropenia [see Warnings and Precautions ( 5.2 )] Interstitial Lung Disease [see Warnings and Precautions ( 5.3 )] Most common adverse reactions (incidence greater than or equal to 5% and greater than placebo) were oral hypoesthesia, asthenia, nausea, decreased lung function, hypertension, and abdominal pain ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aquestive Therapeutics at 1-877-394-5045 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adverse Reactions in Controlled Clinical Trials of Riluzole Tablets In the placebo-controlled clinical trials in patients with ALS (Study 1 and 2), a total of 313 patients received riluzole tablets 50 mg twice daily [see Clinical Studies ( 14 )] . The most common adverse reactions in the riluzole-treated patients (in at least 5% of patients and more frequently than on placebo) were asthenia, nausea, decreased lung function, hypertension, and abdominal pain. The most common adverse reactions leading to discontinuation in the riluzole-treated patients were nausea, abdominal pain, constipation, and elevated ALT. There was no difference in rates of adverse reactions leading to discontinuation in females and males. However, the incidence of dizziness was higher in females (11%) than in males (4%). The adverse reaction profile was similar in older and younger patients. There were insufficient data to determine if there were differences in the adverse reaction profile in different races. Table 1 lists adverse reactions that occurred in at least 2% of riluzole treated patients (50 mg twice daily) in pooled Study 1 and 2, and at a higher rate than placebo. Table 1. Adverse Reactions in Pooled Placebo-Controlled Trials (Studies 1 and 2) in Patients with ALS RILUZOLE Tablets 50 mg twice daily (N=313) % Placeb o (N=320) % Asthenia 19 12 Nausea 16 11 Decreased lung function 10 9 Hypertension 5 4 Abdominal pain 5 4 Vomiting 4 2 Arthralgia 4 3 Dizziness 4 3 Dry mouth 4 3 Insomnia 4 3 Pruritus 4 3 Tachycardia 3 1 Flatulence 3 2 Increased cough 3 2 Peripheral edema 3 2 Urinary tract infection 3 2 Circumoral paresthesia 2 0 Somnolence 2 1 Vertigo 2 1 Eczema 2 1 Additional Adverse Reaction with EXSERVAN In an open-label pharmacokinetic study in healthy subjects (n=32), oral hypoesthesia was observed in 38% of subjects taking EXSERVAN, compared to no subjects taking riluzole tablets, under fasting conditions. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of riluzole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Acute hepatitis and icteric toxic hepatitis [see Warnings and Precautions ( 5.1 )] Renal tubular impairment Pancreatitis
adverse reactions table
<table><caption>Table 1. Adverse Reactions in Pooled Placebo-Controlled Trials (Studies 1 and 2) in Patients with ALS</caption><col width="204"/><col width="201"/><col width="156"/><tbody><tr><td styleCode="Toprule Lrule Rrule "/><td styleCode="Toprule Lrule Rrule " align="center"><content styleCode="bold">RILUZOLE Tablets</content> <content styleCode="bold">50 mg twice daily</content> <content styleCode="bold">(N=313)</content><content styleCode="bold"> %</content></td><td styleCode="Toprule Lrule Rrule " align="center"><content styleCode="bold">Placeb</content><content styleCode="bold">o</content> <content styleCode="bold">(N=320)</content> <content styleCode="bold"> %</content></td></tr><tr><td styleCode="Toprule Lrule Rrule ">Asthenia</td><td styleCode="Toprule Lrule Rrule " align="center">19</td><td styleCode="Toprule Lrule Rrule " align="center">12</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Nausea</td><td styleCode="Toprule Lrule Rrule " align="center">16</td><td styleCode="Toprule Lrule Rrule " align="center">11</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Decreased lung function</td><td styleCode="Toprule Lrule Rrule " align="center">10</td><td styleCode="Toprule Lrule Rrule " align="center">9</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Hypertension</td><td styleCode="Toprule Lrule Rrule " align="center">5</td><td styleCode="Toprule Lrule Rrule " align="center">4</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Abdominal pain</td><td styleCode="Toprule Lrule Rrule " align="center">5</td><td styleCode="Toprule Lrule Rrule " align="center">4</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Vomiting</td><td styleCode="Toprule Lrule Rrule " align="center">4</td><td styleCode="Toprule Lrule Rrule " align="center">2</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Arthralgia</td><td styleCode="Toprule Lrule Rrule " align="center">4</td><td styleCode="Toprule Lrule Rrule " align="center">3</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dizziness</td><td styleCode="Toprule Lrule Rrule " align="center">4</td><td styleCode="Toprule Lrule Rrule " align="center">3</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Dry mouth</td><td styleCode="Toprule Lrule Rrule " align="center">4</td><td styleCode="Toprule Lrule Rrule " align="center">3</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Insomnia</td><td styleCode="Toprule Lrule Rrule " align="center">4</td><td styleCode="Toprule Lrule Rrule " align="center">3</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Pruritus</td><td styleCode="Toprule Lrule Rrule " align="center">4</td><td styleCode="Toprule Lrule Rrule " align="center">3</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Tachycardia</td><td styleCode="Toprule Lrule Rrule " align="center">3</td><td styleCode="Toprule Lrule Rrule " align="center">1</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Flatulence</td><td styleCode="Toprule Lrule Rrule " align="center">3</td><td styleCode="Toprule Lrule Rrule " align="center">2</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Increased cough</td><td styleCode="Toprule Lrule Rrule " align="center">3</td><td styleCode="Toprule Lrule Rrule " align="center">2</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Peripheral edema</td><td styleCode="Toprule Lrule Rrule " align="center">3</td><td styleCode="Toprule Lrule Rrule " align="center">2</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Urinary tract infection</td><td styleCode="Toprule Lrule Rrule " align="center">3</td><td styleCode="Toprule Lrule Rrule " align="center">2</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Circumoral paresthesia</td><td styleCode="Toprule Lrule Rrule " align="center">2</td><td styleCode="Toprule Lrule Rrule " align="center">0</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Somnolence</td><td styleCode="Toprule Lrule Rrule " align="center">2</td><td styleCode="Toprule Lrule Rrule " align="center">1</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Vertigo</td><td styleCode="Toprule Lrule Rrule " align="center">2</td><td styleCode="Toprule Lrule Rrule " align="center">1</td></tr><tr><td styleCode="Toprule Lrule Rrule ">Eczema</td><td styleCode="Toprule Lrule Rrule " align="center">2</td><td styleCode="Toprule Lrule Rrule " align="center">1</td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.